MARLBORO, Mass.--(BUSINESS WIRE)--Xcellerex, Inc. announced today that the company has received two Phase I contracts awarded by the Defense Advanced Research Projects Agency (DARPA) for the Accelerated Manufacture of Pharmaceuticals (AMP) program. The AMP program is a three phase program in which the U.S. military is focused on technologies for producing emergency therapeutics and vaccines, rapidly and cost effectively in order to respond to a wide range of biological threats. Phase I of the AMP program, for which these contracts were awarded, is focused on optimizing host strains that will express a model vaccine and antibody, and demonstrating small scale production. Subsequent phases will be aimed at rapid process optimization, scale up and cost effective production. The total funding for the two Phase I contracts is over $13 million.
